The first phase of Nigeria's campaign will begin in November, targeting Kebbi and Beyelsa states, where malaria activity is especially high.
Researchers say the findings highlight the need for more comprehensive approaches to managing fever in children under 5 in sub-Saharan Africa.
The PfSPZ vaccine was safe and prompted durable protection across 2 years.
Nipah virus, which has a high fatality rate, is a top target for countermeasure development.
The first dose was given in Abidjan, and the rollout will target 38 districts across the country.
Sixty-eight imported malaria cases were identified in Pima, Arizona; San Diego, California; and El Paso, Texas, compared with 28 cases in 2022.
The monoclonal antibody, L9LS, was previously shown to offer 80% protection to adults in a phase 1 trial.
Researchers estimate that 85 pathogens accounted for 704 million disability-adjusted life years globally in 2019.
Vector-borne illnesses have doubled over the past two decades, as the number of pathogens grows and affected areas expand.
Vaccine effectiveness at 1 year was 75% at seasonal sites and 68% at standard sites for time to first malaria infection.